Literature DB >> 26359313

Effects of nicotinic acetylcholine receptor agonists in assays of acute pain-stimulated and pain-depressed behaviors in rats.

Kelen C Freitas1, F Ivy Carroll, S Stevens Negus.   

Abstract

Agonists at nicotinic acetylcholine receptors (nAChRs) constitute one drug class being evaluated as candidate analgesics. Previous preclinical studies have implicated α4β2 and α7 nAChRs as potential mediators of the antinociceptive effects of (–)-nicotine hydrogen tartrate (nicotine) and other nAChR agonists; however, these studies have relied exclusively on measures of pain-stimulated behavior, which can be defined as behaviors that increase in frequency, rate, or intensity after presentation of a noxious stimulus. Pain is also associated with depression of many behaviors, and drug effects can differ in assays of pain-stimulated versus pain-depressed behavior. Accordingly, this study compared the effects of nicotine, the selective α4/6β2 agonist 5-(123I)iodo-3-[2(S)-2-azetidinylmethoxy]pyridine (5-I-A-85380), and the selective α7 agonist N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-4-chlorobenzamide in assays of pain-stimulated and pain-depressed behavior in male Sprague-Dawley rats. Intraperitoneal injection of dilute lactic acid served as an acute noxious stimulus to either stimulate a stretching response or depress the operant responding, which is maintained by electrical brain stimulation in an intracranial self-stimulation (ICSS) procedure. Nicotine produced a dose-dependent, time-dependent, and mecamylamine-reversible blockade of both acid-stimulated stretching and acid-induced depression of ICSS. 5-I-A-85380 also blocked both acid-stimulated stretching and acid-induced depression of ICSS, whereas N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-4-chlorobenzamide produced no effect in either procedure. Both nicotine and 5-I-A-85380 were ≥10-fold more potent in blocking the acid-induced depression of ICSS than in blocking the acid-induced stimulation of stretching. These results suggest that stimulation of α4β2 and/or α6β2 nAChRs may be especially effective to alleviate the signs of pain-related behavioral depression in rats; however, nonselective behavioral effects may contribute to apparent antinociception.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26359313      PMCID: PMC4613961          DOI: 10.1124/jpet.115.226803

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  76 in total

1.  Rationale and methods for assessment of pain-depressed behavior in preclinical assays of pain and analgesia.

Authors:  S Stevens Negus; Edward J Bilsky; Gail Pereira Do Carmo; Glenn W Stevenson
Journal:  Methods Mol Biol       Date:  2010

2.  MD-354 selectively antagonizes the antinociceptive effects of (-)nicotine in the mouse tail-flick assay.

Authors:  Małgorzata Dukat; Anna Wesołowska; Genevieve Alley; Shawquia Young; Galya R Abdrakhmanova; Hernán A Navarro; Richard Young; Richard A Glennon
Journal:  Psychopharmacology (Berl)       Date:  2010-04-30       Impact factor: 4.530

3.  Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.

Authors:  V Gerzanich; X Peng; F Wang; G Wells; R Anand; S Fletcher; J Lindstrom
Journal:  Mol Pharmacol       Date:  1995-10       Impact factor: 4.436

4.  Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats.

Authors:  P Whiteaker; H S Garcha; S Wonnacott; I P Stolerman
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

5.  Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.

Authors:  Krista Spiller; Zheng-Xiong Xi; Xia Li; Charles R Ashby; Patrick M Callahan; Ashok Tehim; Eliot L Gardner
Journal:  Neuropharmacology       Date:  2009-04-22       Impact factor: 5.250

6.  A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models.

Authors:  Jianguo Ji; William H Bunnelle; David J Anderson; Connie Faltynek; Tino Dyhring; Philip K Ahring; Lynne E Rueter; Peter Curzon; Michael J Buckley; Kennan C Marsh; Anita Kempf-Grote; Michael D Meyer
Journal:  Biochem Pharmacol       Date:  2007-08-12       Impact factor: 5.858

7.  Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior.

Authors:  Gail Pereira Do Carmo; Glenn W Stevenson; William A Carlezon; S Stevens Negus
Journal:  Pain       Date:  2009-05-10       Impact factor: 6.961

8.  Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (NAChR) ligands in the rat tail-flick assay.

Authors:  T S Rao; L D Correa; R T Reid; G K Lloyd
Journal:  Neuropharmacology       Date:  1996-04       Impact factor: 5.250

Review 9.  Animal models of pain: progress and challenges.

Authors:  Jeffrey S Mogil
Journal:  Nat Rev Neurosci       Date:  2009-03-04       Impact factor: 34.870

10.  Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats.

Authors:  S Stevens Negus; Ember M Morrissey; Marisa Rosenberg; K Cheng; Kenner C Rice
Journal:  Psychopharmacology (Berl)       Date:  2010-01-26       Impact factor: 4.530

View more
  10 in total

1.  Altered nocifensive behavior in animal models of autism spectrum disorder: The role of the nicotinic cholinergic system.

Authors:  Li Wang; Luis E F Almeida; Margaret Nettleton; Alfia Khaibullina; Sarah Albani; Sayuri Kamimura; Mehdi Nouraie; Zenaide M N Quezado
Journal:  Neuropharmacology       Date:  2016-09-13       Impact factor: 5.250

Review 2.  Pros and Cons of Clinically Relevant Methods to Assess Pain in Rodents.

Authors:  Anke Tappe-Theodor; Tamara King; Michael M Morgan
Journal:  Neurosci Biobehav Rev       Date:  2019-03-15       Impact factor: 8.989

Review 3.  α9-containing nicotinic acetylcholine receptors and the modulation of pain.

Authors:  Arik J Hone; Denis Servent; J Michael McIntosh
Journal:  Br J Pharmacol       Date:  2017-07-30       Impact factor: 8.739

4.  Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.

Authors:  Matthew L Lazenka; Megan J Moerke; E Andrew Townsend; Kevin B Freeman; F Ivy Carroll; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2017-10-24       Impact factor: 4.530

5.  Relief of Pain-Depressed Behavior in Rats by Activation of D1-Like Dopamine Receptors.

Authors:  Matthew F Lazenka; Kelen C Freitas; Sydney Henck; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2017-04-14       Impact factor: 4.030

6.  Central α7 and α4β2 nicotinic acetylcholine receptors offset arterial baroreceptor dysfunction in endotoxic rats.

Authors:  Marwa Y Sallam; Sahar M El-Gowilly; Mahmoud M El-Mas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-09-14       Impact factor: 3.195

Review 7.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

8.  Effect of nicotine and alpha-7 nicotinic modulators on visceral pain-induced conditioned place aversion in mice.

Authors:  D Bagdas; J A Meade; Y Alkhlaif; P P Muldoon; F I Carroll; M I Damaj
Journal:  Eur J Pain       Date:  2018-04-10       Impact factor: 3.931

9.  The nAChR Chaperone TMEM35a (NACHO) Contributes to the Development of Hyperalgesia in Mice.

Authors:  Sergey G Khasabov; Victoria M Rogness; Montana B Beeson; Lucy Vulchanova; Li-Lian Yuan; Donald A Simone; Phu V Tran
Journal:  Neuroscience       Date:  2021-01-07       Impact factor: 3.590

10.  The Spinal α7-Nicotinic Acetylcholine Receptor Contributes to the Maintenance of Cancer-Induced Bone Pain.

Authors:  Ting Yang; Yaqun Zhou; Wen Zhang; Longqing Zhang; Shuping Chen; Chao Chen; Feng Gao; Hui Yang; Anne Manyande; Jie Wang; Yuke Tian; Xuebi Tian
Journal:  J Pain Res       Date:  2021-02-15       Impact factor: 3.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.